Topics Include:
Basic & Translational Science of Psychedelics | Clinical Models: Ketamine, Psilocybin, and Ibogaine | Global Practices & Comparative Frameworks | Legal & Policy Pathways for Regulation | Therapeutic Facilitation & Patient Journeys | Coverage Models & Health System Integration | Industry & Manufacturing Perspectives | Economics of Psychedelic Therapies | Patient Perspectives & Family Narratives | Future Directions: Implementation, Barriers, & Spirituality
Speakers
Keynote Speaker
Psilocybin, Ibogaine, and Ketamine: the Basic and Translational Science
Professor of Psychiatry, Perelman School of Medicine
How Ketamine/Esketamine Opened the Doors to Psychedelics Research
Research Assistant Professor of Psychiatry, Perelman School of Medicine
Penn’s Clinical Trial of Psilocybin for OUD
Professor of Chemistry and The Zuckerman Mind Brain Behavior Institute, Columbia University
Mechanisms of Ibogaine and Multidimensional Therapeutic Potential
Adjunct Professor of Psychiatry, Perelman School of Medicine
Long Day's Journey into Psilocybin Research: Local and Regional Barriers (Virtual)
Therapeutic and Clinical Perspectives
Therapeutic and Clinical Applications
Medical Director, Inscape Recovery
Current Modes of Ibogaine Practice in Mexico (Virtual)
Patrick Fishley, RN BScN CCRN
& Michele Fishley, LPN
Iboga Practitioners, Soul Reflections Int'l
Road Maps and Barriers to adding Ibogaine to the US Model
Physician; Chacruna Institute for Psychedelic Plant Medicines
Ibogaine’s Clinical Success in Brazil, and Legal Roadblocks Beyond Drug Scheduling (Virtual)
Founder and Executive Director, MediRootz Medical Group
Ibogaine and the US Medical Model
Founder, The Mission Within treatment center
5-MeO-DMT Treatment Applications (Virtual)
Psilocybin-Assisted Therapy Educational Play
Editor of Netflix’s How to Change Your Mind,
CEO, Psychedelic Oncology
Founder, NJ for Fungi and Plant Medicines
Therapist, New Jersey Psychedelic
Therapy Association
Physician; Psychedelic Oncology; Memorial Sloan Kettering Cancer Center
Public and Private Coverage Models
Enthea; California Institute of Integral Studies; Psychedelic Research Group
Founder, CannaCoverage of Trenton, NJ
Chief of Staff, Journey Clinical
Independent KAT Clinician
Legal Considerations
Attorney, Law Office of Robert T. Rush;
Rights and Reason Project
DEA vs. Psychedelic Science: The Fight to Save DOI
Executive Director, Coalition for Medical Marijuana-NJ;
Chairman, Trenton Cannabis Advisory Committee
Current Legal Frameworks
Patient Experiences
End-of-Life Doula;
Certified Dementia Care Specialist
Veteran, United States Air Force
(2001-2007)
Coalition for Medical Marijuana-NJ, Inc.;
Americans for Safe Access
Andrew Walker
Veteran
Heroic Hearts Project
Board-Certified Psychiatric-Mental Health Nurse Practitioner
Clusterbusters / FDNY (ret.)
